Ex vivo expansion of dendritic-cell-activated antigen-specific CD4 + T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: Potential for adoptive T cell immunotherapy

Clinical Immunology

Volumn 119, Issue 1, 2006, Pages 21-31

  Chen, Hao Wei ^a   Liao, Cheng Hao ^a   Ying, Chingwen ^a   Chang, Chun Jung ^a   Lin, Chun Ming ^a  

^a SOOCHOW UNIVERSITY   (Taiwan)

Author keywords

Adoptive immunotherapy; CD4+ T cells; Interleukin 7 15; NKG2D

Indexed keywords

ANTIGEN; CD137 ANTIGEN; CD3 ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 7; MONOCLONAL ANTIBODY CD28; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CELL DEATH; CELL SPECIFICITY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; HEPATITIS B VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; UPREGULATION;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD3; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DENDRITIC CELLS; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; INTERLEUKINS; LYMPHOCYTE ACTIVATION; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-2; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33644750124     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2005.11.003     Document Type: Article

References (48)

1. S.R. Riddell, and P.D. Greenberg Principles for adoptive T cell therapy of human viral diseases Annu. Rev. Immunol. 13 1995 545 586
2. M.E. Dudley, J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, M.R. Robinson, M. Raffeld, P. Duray, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
3. S.A. Rosenberg Progress in human tumor immunology and immunotherapy Nature 411 2001 380 384
4. M.H. Kershaw, J.A. Westwood, and P. Hwu Dual-specific T cells combine proliferation and antitumor activity Nat. Biotechnol. 20 2002 1221 1227
5. R.J. Brentjens, J.B. Latouche, E. Santos, F. Marti, M.C. Gong, C. Lyddane, P.D. King, S. Larson, M. Weiss, I. Riviere, and M. Sadelain Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat. Med. 9 2003 279 286
6. D. Montagna, R. Maccario, F. Locatelli, V. Rosti, Y. Yang, P. Farness, A. Moretta, P. Comoli, E. Montini, and A. Vitiello Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy Blood 98 2001 3359 3366
7. + T cells have a major post-licensing role in CTL mediated anti-tumor immunity J. Immunol. 165 2000 6047 6055
8. R.E. Walker, C.M. Bechtel, V. Natarajan, M. Baseler, K.M. Hege, J.A. Metcalf, R. Stevens, A. Hazen, R.M. Blaese, C.C. Chen, S.F. Leitman, J. Palensky, J. Wittes, R.T. Davey, J. Falloon, M.A. Polis, J.A. Kovacs, D.F. Broad, B.L. Levine, M.R. Roberts, H. Masur, and H.C. Lane Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection Blood 96 2000 467 474
9. + T cells Eur. J. Immunol. 32 2002 374 382
10. R.L. Giuntoli, J. Lu, H. Kobayashi, R. Kennedy, and E. Celis Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function Clin. Cancer Res. 8 2002 922 931
11. S.A. Pilon, C. Kelly, and W.Z. Wei Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor J. Immunol. 170 2003 1202 1208
12. R.E. Toes, F. Ossendrop, R. Offringa, and C.J. Melief CD4 T cells and their role in antitumor immune responses J. Exp. Med. 189 1999 753 756
13. M.E. Dudley, J.R. Wunderlich, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R.M. Sherry, F.M. Marincola, S.F. Leitman, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, A. Nahvi, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma J. Immunother. 25 2002 243 251
14. R. Lapointe, R.E. Royal, M.E. Reeves, I. Altomare, P.F. Robbins, and P. Hwu Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100 J. Immunol. 167 2001 4758 4764
15. L. Chaperot, I. Perrot, M.C. Jacob, D. Blanchard, V. Salaun, V. Deneys, S. Lebecque, F. Briere, J.C. Bensa, and J. Plumas Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts Eur. J. Immunol. 34 2004 418 426
16. T. Kurokawa, M. Oelke, and A. Mackensen Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells Int. J. Cancer 91 2001 749 756
17. P. Romero, P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.-L. Chen, D. Lienard, J.-C. Cerottini, and V. Cerundolo Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J. Exp. Med. 188 1998 1641 1650
18. P.P. Lee, C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, M. Roederer, and M.M. Davis Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat. Med. 5 1999 677 685
19. S.E. Strome, B. Martin, D. Flies, K. Tamada, A.I. Chapoval, D.J. Sargent, S. Shu, and L. Chen Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex I-negative A9P melanoma J. Immunother. 23 2000 430 437
20. F. Ito, A. Carr, H. Svensson, J. Yu, A.E. Chang, and Q. Li Antitumor reactivity of anti-CD3/antiCD28 bead-activated lymphoid cells: implications for cell therapy in a murine model J. Immunother. 26 2003 222 233
21. + T cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 1969 1974
22. S.R. Riddell, and P.D. Greenberg The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells J. Immunol. Methods 128 1990 189 201
23. A.K. Thomas, M.V. Maus, W.S. Shalaby, C.H. June, and J.L. Riley A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes Clin. Immunol. 105 2002 259 272
24. Q. Li, S.A. Furman, C.R. Bradford, and A.E. Chang Expanded tumor-reactive CD4 T cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation Clin. Cancer Res. 5 1999 461 469
25. A. Reddy, M. Sapp, M. Feldman, M. Subklewe, and N. Bhardwaj A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells Blood 90 1997 3640 3646
26. + T cells by retroviral-mediated gene transfer and in vitro sensitization with dendritic cells Clin. Immunol. 104 2002 58 66
27. + T cells Int. Immunol. 14 2002 1155 1167
28. H.C. Hsu, T.T. Wu, J.C. Sheu, C.Y. Wu, T.J. Chiou, C.S. Lee, and D.S. Chen Biologic significance of the detection of HBsAg and HBcAg in liver and tumor from 204 HBsAg-positive patients with primary hepatocellular carcinoma Hepatology 9 1989 747 750
29. Y. Ilan, E. Gabay, G. Amit, R. Feder, E. Galun, R. Adler, and D. Shouval Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen J. Hepatol. 27 1997 170 175
30. L. Garderet, V. Snell, D. Przepiorka, T. Schenk, J.G. Lu, F. Marini, E. Gluckman, M. Andreeff, and R.E. Champlin Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations Transplantation 67 1999 124 130
31. + cytotoxic T cells from virus naive individuals J. Immunol. 168 2002 909 918
32. + T cells J. Exp. Med. 194 2001 1711 1719
33. + T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis J. Immunol. 171 2003 61 68
34. + effector-memory T cells Int. Immunol. 15 2003 49 58
35. J.N. Blattman, J.M. Grayson, E.J. Wherry, S.M. Kaech, K.A. Smith, and A. Ahmed Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo Nat. Med. 9 2003 540 547
36. + T cells prepared for adoptive immunotherapy Immunol. Lett. 86 2003 37 43
37. V. Groh, J. Wu, C. Yee, and T. Spies Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation Nature 419 2002 734 738
38. H.R. Salih, S.G. Kosowski, V.F. Haluska, G.C. Starling, D.T. Loo, F. Lee, A.A. Aruffo, P.A. Trail, and P.A. Kiener Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells J. Immunol. 165 2000 2903 2911
39. V. Groh, A. Bruhl, H. El-Gabalawy, J.L. Nelson, and T. Spies Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis Proc. Natl. Acad. Sci. U. S. A. 100 2003 9452 9457
40. S.M. Kaech, E.J. Wherry, and R. Ahmed Effector and memory T cell differentiation: implications for vaccine development Nat. Rev., Immunol. 2 2002 251 262
41. J. Marks-Konczalik, S. Dubois, J.M. Losi, H. Sabzevari, N. Yamada, L. Feigenbaum, T.A. Waldmann, and Y. Tagaya IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice Proc. Natl. Acad. Sci. U. S. A. 97 2000 11445 11450
42. U. Sili, M.H. Huls, A.R. Davis, S. Gottschalk, M.K. Brenner, H.E. Heslop, and C.M. Rooney Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy J. Immunother. 26 2003 241 256
43. M.V. Maus, A.K. Thomas, D.G.B. Leonard, D. Allman, K. Addya, K. Schlienger, J.L. Riley, and C.H. June Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat. Biotechnol. 20 2002 143 148
44. A. Krause, H.-F. Guo, J.-B. Latouche, C. Tan, N.K.V. Cheung, and M. Sadelain Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J. Exp. Med. 188 1998 619 626
45. X.F. Bai, J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu Local costimulation reinvigorates tumor-specific cytotoxic T lymphocytes for experimental therapy in mice with large tumor burdens J. Immunol. 167 2001 3936 3943
46. T.T. Chang, C. Jabs, R.A. Sobel, V.K. Kuchroo, and A.H. Sharpe Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis J. Exp. Med. 190 1999 733 740
47. G.L. Costa, M.R. Sandora, A. Nakajima, E.V. Nguyen, C. Taylor-Edwards, A.J. Slavin, C.H. Contag, C.G. Fathman, and J.M. Benson Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit J. Immunol. 167 2001 2379 2387
48. + T cells do not induce graft-versus-host disease J. Clin. Invest. 112 2003 101 108